Oliver Grauer
Overview
Explore the profile of Oliver Grauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pepper N, Steike D, Ypparila-Wolters H, Muther M, Wiewrodt D, Berssenbrugge H, et al.
Strahlenther Onkol
. 2025 Jan;
PMID: 39843784
Purpose: While glioblastoma is the most common malignant brain tumor in adults, extracerebral manifestations are very rare in this highly aggressive disease with poor prognosis. Methods: We conducted a systematic...
2.
Pepper N, Prange N, Troschel F, Kroger K, Oertel M, Kuhlmann T, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518091
Background: Glioblastoma is the most common malignant brain tumor in adults. Even after maximal safe resection and adjuvant chemoradiotherapy, patients normally relapse after a few years or even months. Standard...
3.
Rauber S, Schulte-Mecklenbeck A, Willison A, Hagler R, Jonas M, Pul D, et al.
J Neuroinflammation
. 2024 Nov;
21(1):286.
PMID: 39497174
Background: Immune dysregulation is a hallmark of autoimmune diseases of the central nervous system (CNS), characterized by an excessive immune response, and primary CNS tumors (pCNS-tumors) showing a highly immunosuppressive...
4.
Zeyen T, Bohm L, Paech D, Schafer N, Tzaridis T, Duffy C, et al.
Neuro Oncol
. 2024 Oct;
27(2):557-566.
PMID: 39351820
Background: Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The response assessment in neuro-oncology (RANO) resects group recently proposed...
5.
Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C, et al.
J Neurooncol
. 2023 Nov;
165(2):387.
PMID: 37921974
No abstract available.
6.
Harms J, Streckert E, Kiolbassa N, Thomas C, Grauer O, Oertel M, et al.
Neurosurg Rev
. 2023 Oct;
46(1):286.
PMID: 37891361
Although frozen section pathology (FSP) is commonly performed during surgery for glioma-suspicious lesions, confounders of accuracy are largely unknown. FSP and final diagnosis were compared in 398 surgeries for glioma-suspicious...
7.
Zeyen T, Paech D, Weller J, Schafer N, Tzaridis T, Duffy C, et al.
J Neurooncol
. 2023 Sep;
164(3):607-616.
PMID: 37728779
Purpose: In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were...
8.
Feldheim J, Schmidt T, Oster C, Feldheim J, Stuschke M, Stummer W, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627083
In order to minimize the risk of infections during the COVID-19 pandemic, remote video consultations (VC) experienced an upswing in most medical fields. However, telemedicine in neuro-oncology comprises unique challenges...
9.
Kopf L, Warneke N, Grauer O, Thomas C, Hess K, Schwake M, et al.
Neurosurg Rev
. 2023 Feb;
46(1):55.
PMID: 36781550
Synchronous or metachronous growth of multiple tumors (≥ 2) is found in up to 20% of meningioma patients. However, biological as well as histological features and prognosis are largely unexplored....
10.
Lazaridis L, Bumes E, Spille D, Schulz T, Heider S, Agkatsev S, et al.
Neurooncol Adv
. 2022 Oct;
4(1):vdac137.
PMID: 36284931
Background: The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosed promoter methylated glioblastoma patients. Survival was significantly improved from 31.4...